The salvinorins are a small group of trans-neoclerodane diterpenes isolated from the leaves of Salvia divinorum, a mint-family plant native to the Mazatec Sierra of Oaxaca, Mexico; the class is defined by this shared chemical scaffold and its single botanical origin.[1] Membership is narrow and chemically tight — one source plant and a small family of structurally related congeners.
The class spans the intact plant material, Salvia divinorum, and its isolated principal active compound, salvinorin A, alongside minor congeners such as salvinorin B that share the scaffold without sharing potent activity. Across this narrow scope the members converge on the same pharmacology: selective kappa-opioid receptor agonism, with salvinorin A the first naturally occurring non-nitrogenous compound known to act through this receptor.[2]
In use, the class produces rapid-onset, brief, and intense dissociation when absorbed quickly — typically by smoking the dried leaf or the isolated compound — and a milder, more gradual experience when fresh leaf is chewed in the Mazatec traditional preparation. Effects range from subtle somaesthetic and perceptual changes at low exposure to profound spatiotemporal dislocation and motor incapacitation at high exposure.[3]
Pharmacology
The salvinorin class converges on a single, well-characterised mechanism: selective full agonism at the kappa-opioid receptor (KOR).[2] Salvinorin A — the class prototype — was screened against fifty receptors, transporters, and ion channels and showed potent activity only at the KOR, with no measurable affinity for serotonergic, dopaminergic, or other classical hallucinogen targets.[2] The unifying property of the class is therefore both chemical (the trans-neoclerodane scaffold, lacking any nitrogen atom) and pharmacological (a single high-affinity receptor target).
| Feature | Class property |
|---|---|
| Chemical scaffold | trans-neoclerodane diterpene; non-nitrogenous |
| Primary target | Kappa-opioid receptor (KOR), Gi/o-coupled |
| Other classical hallucinogen targets | No measurable activity at 5-HT2A, NMDA, or related sites |
| Critical structural feature | C-2 acetate; its loss (salvinorin B) abolishes KOR binding |
| Pharmacokinetics (inhaled) | Brain peak within seconds; brain half-life of minutes |
At the cellular level, KOR is a Gi/o-coupled receptor whose activation suppresses adenylyl cyclase, modulates voltage-gated calcium channels, and opens inwardly rectifying potassium channels — the same cascades engaged by the endogenous dynorphin peptides.[4] In mesolimbic and mesocortical circuits this signalling acts as a counter-regulatory brake on dopaminergic reward, which is why KOR agonists characteristically lack euphoria and, in preclinical models, produce aversion and anhedonia.[4]
The class's distinctive time course is set by its pharmacokinetics. PET imaging with carbon-11–labelled salvinorin A in primates showed that the compound enters the brain within roughly forty seconds of inhalation and clears with a brain half-life of about eight minutes.[5] In-vitro metabolism work attributes this rapid clearance to esterase hydrolysis of the C-2 acetate and oxidative metabolism by several CYP450 isoforms.[6]
The KOR-mediated nature of the experience has been confirmed in humans by selective-antagonist studies: in controlled work, naltrexone abolished both the subjective and the physiological effects of inhaled salvinorin A, while the 5-HT2A antagonist ketanserin did not.[7]
Substances
The class is unusually narrow — a single source plant and a single principal active molecule — and is best illustrated by the two members named in the brief:
| Member | Form | Role / distinctive feature |
|---|---|---|
| Salvia divinorum | Whole plant | Botanical source; contains salvinorin A alongside structurally related congeners (salvinorin B and minor neoclerodanes); traditionally prepared as chewed fresh leaf or expressed juice in Mazatec practice |
| Salvinorin A | Isolated compound | Principal active constituent and the prototype KOR agonist of the class; the only member with confirmed potent psychoactivity at naturally occurring concentrations |
The plant's effect profile largely reflects that of its dominant active constituent, with modulating contributions from minor congeners; congeners that lack the C-2 acetate, such as salvinorin B, lack meaningful KOR binding and so contribute little to the experience.
Subjective Effects
The class produces orderly, dose-related effects that peak within roughly two minutes of inhalation and dissipate quickly afterward.[3] The defining phenomenology is intense dissociation accompanied by somaesthetic distortion, spatiotemporal dislocation, and memory impairment — a profile qualitatively distinct from classical serotonergic hallucinogens and from NMDA-antagonist dissociatives.[3]
| Exposure | Characteristic effects |
|---|---|
| Low | Mild somaesthetic changes (warmth, pressure, body distortion), light-headedness, and subtle perceptual shifts |
| Moderate–high | Pronounced dissociation, spatiotemporal dislocation, vivid and often non-volitional imagery, depersonalisation, memory impairment, and partial loss of coordinated movement |
| High | Profound loss of contact with ordinary sensory reality, complete motor incapacitation during the peak window, and amnesia for the experience itself |
Controlled studies in experienced users have characterised these effects across the Hallucinogen Rating Scale and confirm they are dose-orderly rather than capricious.[8] The safety hinge of the class is that the same axis that deepens the experience also drives the incapacitation: as exposure rises, the margin between a manageable session and a peak in which the user is unresponsive to their surroundings narrows rapidly.[9]
Safety
Risk profile
The defining acute danger of the salvinorin class is complete motor incapacitation and unresponsiveness during the brief peak window. An unsupervised user can fall, walk into traffic or water, or otherwise come to physical harm during a period in which they cannot perceive or respond to their surroundings. A sober sitter and a safe, enclosed setting for the duration of effects are the most reliable harm-reduction steps for the class.
Beyond physical-injury risk, the class can produce severe acute psychological distress — panic, confusion, and depersonalisation — particularly in inexperienced users and in unstructured settings.[10] Case reports document lasting psychotic disturbances in vulnerable individuals after high-dose exposure, and a personal or family history of psychosis is a meaningful contraindication.[10]
Controlled human work has documented dose-dependent increases in plasma cortisol and prolactin and modest cardiovascular activation, consistent with KOR-mediated stress-axis engagement; pre-existing cardiovascular disease is therefore a further caution.[7]
Combination data with other substances are sparse, but additive sedation and impaired coordination with CNS depressants is a foreseeable concern, and combinations with classical serotonergic hallucinogens or monoamine oxidase inhibitors have not been characterised in controlled human studies. The amnestic effects of the class also mean a user may be unable to recall or coherently report a distressing experience immediately afterward.[3]
Tolerance & dependence
Rapid within-session tachyphylaxis is reported and is consistent with KOR desensitisation; cross-tolerance between plant preparations and isolated salvinorin A is expected from the shared mechanism.[4] Systematic human tolerance studies remain sparse.
Controlled human work consistently points to a low addiction potential for the class. Salvinorin A does not produce euphoria, and KOR agonism in preclinical models is associated with aversion and anhedonia rather than the positive reinforcement that drives compulsive opioid or stimulant use.[4]
No clinically recognised physical-dependence syndrome and no characterised withdrawal syndrome have been documented for the class, and authors of controlled studies have explicitly noted a low addictive potential alongside the absence of euphoria.[7]
Recovery
Because no physical-dependence syndrome has been documented for the salvinorin class, recovery from problematic use does not require medical detoxification of the kind needed for alcohol, benzodiazepines, or classical opioids. The clinically relevant concerns are psychological: working through distressing or disorienting experiences, addressing any precipitated or unmasked psychotic symptoms, and supporting underlying mental health. A clinician, therapist, or integration-focused practitioner is the appropriate point of contact.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^Ortega A, Blount J, Manchand P (1982) Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae) — Journal of the Chemical Society, Perkin Transactions 1 doi:10.1039/p19820002505
- [2] ^abcRoth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. — Proceedings of the National Academy of Sciences of the United States of America PMID:12192085
- [3] ^abcdMacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. — Psychopharmacology doi:10.1007/s00213-012-2912-9
- [4] ^abcdButelman ER, Kreek MJ (2015) Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders — Frontiers in Pharmacology doi:10.3389/fphar.2015.00190
- [5] ^Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS (2008) Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. — NeuroImage doi:10.1016/j.neuroimage.2008.03.003
- [6] ^Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, Syed SS, Prisinzano TE, Eddington ND (2009) Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen — European Journal of Pharmaceutics and Biopharmaceutics doi:10.1016/j.ejpb.2009.01.002